FTRP News and Press, Field Trip Health Ltd. From 03/02/22

A psychedelic experience can be very gratifying, and indeed, profoundly life-changing. As the demand grows for having such an experience, new ways to go on that journey in a safe and complete manner outside of a clinical trial have emerged. These are not the psychedeli...

Title: Field Trip Health Ltd (FTRP) Q3 2022 Earnings Conference Call 16, February, 2022, 8:30 AM ET Company Participants Joseph Del Moral – Co-Founder and Chief Executive Officer Ronan Levy – Co-Founder and Executive Chairman Donna Wong – Chief Financial Officer Kathleen ...

Field Trip Health  press release (NASDAQ:FTRP): FQ3 GAAP EPS of -$0.26 misses by $0.08. Revenue of $1.36M (+325.0% Y/Y) beats by $0.15M. Shares +1.16% AH. For further details see: Field Trip Health  GAAP EPS of -$0.26 misses by $0.08, revenue of $1.36M beats by $0.15M

Field Trip Health Ltd. (NASDAQ: FTRP) reported its third fiscal quarter 2022 results for the three months ending December 31, 2021 and gave a business update. Field Trip reported that it had earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and ...

Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year. At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash and cash equivalents and short-term investments. Received Notice of Allowance fo...

Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...

This is being republished from Crain Chicago and was written by Jon Asplund. Psychedelics are going legitimate, looking to trade a reputation as illicit, illegal party drugs for legal, approved treatments for medical problems like depression, anxiety, post-traumatic stress dis...

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal third quarter ended Decemb...

It wasn’t that long ago when psychedelics emerged as a potentially better natural plant-based medicine for treating such things as treatment-resistant depression (TRD), into what is now a billion-dollar juggernaut of an industry. Then an even curiouser thing happened....

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific ...